.Price to Operating Profit (P/OP) since 2012
Difficulty: Beginner
Calculation
AbbVie Inc., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2013 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2014 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2015 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2016 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2017 | = | ÷ | = | ÷ |
1 USD $
2 Data adjusted for splits and stock dividends.
3 Close price on the filing date of AbbVie Inc.'s Annual Report.
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Competitors
AbbVie Inc., P/OP, long-term trends, comparison to competitors
| AbbVie Inc. | Abbott Laboratories | Allergan PLC | Amgen Inc. | Biogen Inc. | Celgene Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | ||||||||
| Dec 31, 2013 | ||||||||
| Dec 31, 2014 | ||||||||
| Dec 31, 2015 | ||||||||
| Dec 31, 2016 | ||||||||
| Dec 31, 2017 |
Source: Based on data from AbbVie Inc. Annual Reports
